What are Extracellular Vesicles (EVs)? EVs are membrane-enclosed nanoparticles that contain diverse molecular cargo (e.g., RNA, protein) released by cells in the body. EVs can be accessed through liquid biopsies, a minimally invasive alternative to surgical biopsies that can enable easier detection of a broad range of diseases. One of the key advantages of EVs in diagnostics is their ability to reflect the molecular status of cells, including the presence of disease, making them ideal candidates for the development of disease biomarkers. The utilization of EVs as a source of biomarkers in disease detection and monitoring is poised to revolutionize the field of liquid biopsy diagnostics.
We are leveraging a multitude of data sources in FYR’s EVO-PlatformTM, including genomics, transcriptomics, and proteomics. Our focus is on unlocking the full potential of EVs as the engine behind our multiomics approach. To fully realize the benefits of our approach, we are actively developing and implementing a range of innovative tools and techniques specifically designed to leverage EVs as a unique window into biology. Our team of experts is refining and enhancing EV-focused machine learning models to support data-driven decisions, ensuring that we are at the forefront of innovation in the field.
Selective Protein Affinity Reagent Chemistries (SPARCsTM). Proprietary targeting technology for disease or tissue associated EV subpopulation isolation. Helps to enrich disease and tissue associated biomarkers. Finding markers of disease is like finding a needle in a haystack, and SPARCs help “reduce the size of the haystack”, which has the potential to enable better patient stratification, provide more details on disease, and increase chances of finding disease earlier.
We fuel new relationships, collaborations, and strategic partnerships involving multiomics target discovery and diagnostic test development. Let’s kindle the next generation of innovation together. To learn more about our innovations in diagnostics and EV research, contact us.